Citius Oncology, Inc. (NASDAQ:CTOR) Financings

Citius Oncology, Inc.

Financings

RaiseDate
Senior secured term loan with warrants
Announced: US$10M–US$25M · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Avenue Venture Opportunities Fund II, L.P. (up to $25 million senior secured term loan credit facility)
Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes
May 5, 2026
Warrant exercise of exercise of outstanding warrants for common stock
Announced: about US$11.5M · US$0.9 a share · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes
May 5, 2026
Registered direct offering of common stock with unregistered warrants
Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes
Dec 10, 2025
Private placement of common stock (or pre-funded warrants) and warrants
Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes
Dec 10, 2025
Registered direct offering of common stock with accompanying unregistered warrants
Closed: US$9M raised · US$1.75 a share · ½ warrant at US$1.84 for 66 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Sep 10, 2025
Public offering of common stock and warrants
Closed: US$9M raised · US$1.32 a share · Warrants at US$1.32 for 60 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Commercialization of LYMPHIR, including license milestone and royalty payments, plus working capital and general corporate purposes
Jul 17, 2025

Read by 6ix AI from the company's releases